Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RevealDx markets RevealAI-Lung, an AI and radiomics-based software that computes a malignancy similarity index (mSI) for lung nodules on CT, aiming to accelerate diagnosis, reduce false positives and unnecessary procedures, and has shown in clinical research an earlier diagnosis in a substantial fraction of cancers with a 29–33% false-positive reduction when combined with Lung-RADS in screening cohorts.[3][4]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RevealDx.